We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

60 hedge funds and large institutions have $60.8M invested in Theriva Biologics in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 9

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

2% less funds holding

Funds holding: 61 → 60 (-1)

5% less capital invested

Capital invested by funds: $64.2M → $60.8M (-$3.39M)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

Holders
60
Holders Change
-1
Holders Change %
-1.64%
% of All Funds
1.6%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
6
Increased
17
Reduced
9
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
+$150K
2
State Street
State Street
Massachusetts
+$120K
3
New York State Common Retirement Fund
New York State Common Retirement Fund
New York
+$59.9K
4
Wells Fargo
Wells Fargo
California
+$59.9K
5
Fisher Asset Management
Fisher Asset Management
Washington
+$44.9K

Top Sellers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
-$224K
2
William Blair & Company
William Blair & Company
Illinois
-$180K
3
Millennium Management
Millennium Management
New York
-$92K
4
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$74.8K
5
M&T Bank
M&T Bank
New York
-$66K
Name Holding Trade Value Shares
Change 		Change in
Stake
SBIA
26
Sheaff Brock Investment Advisors
Indiana
$149K – – –
LTFS
27
Ladenburg Thalmann Financial Services
Florida
$148K – – –
RhumbLine Advisers
28
RhumbLine Advisers
Massachusetts
$140K +$15K +1 +13%
Cambridge Investment Research Advisors
29
Cambridge Investment Research Advisors
Iowa
$131K – – –
Creative Planning
30
Creative Planning
Kansas
$95K +$29.9K +2 +50%
Fisher Asset Management
31
Fisher Asset Management
Washington
$86K +$44.9K +3 +100%
NFA
32
Nationwide Fund Advisors
Ohio
$82K – – –
AIG
33
American International Group
New York
$75.1K – – –
Royal Bank of Canada
34
Royal Bank of Canada
Ontario, Canada
$74K – – –
BA
35
BlackRock Advisors
Delaware
$74K +$15K +1 +25%
HighTower Advisors
36
HighTower Advisors
Illinois
$72K – – –
Wells Fargo
37
Wells Fargo
California
$62K +$59.9K +4 New
New York State Common Retirement Fund
38
New York State Common Retirement Fund
New York
$58K +$59.9K +4 New
RCP
39
Rothschild Capital Partners
New York
$52K +$44.9K +3 New
VKH
40
Virtu KCG Holdings
New York
$50K -$59.9K -4 -57%
CS
41
Credit Suisse
Switzerland
$49K -$15K -1 -25%
Goldman Sachs
42
Goldman Sachs
New York
$48K +$29.9K +2 +200%
Stifel Financial
43
Stifel Financial
Missouri
$45K – – –
PAG
44
Private Advisor Group
New Jersey
$44K +$29.9K +2 +200%
HLA
45
Hamilton Lane Advisors
Pennsylvania
$41K – – –
WS
46
Wedbush Securities
California
$38K – – –
Manulife (Manufacturers Life Insurance)
47
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$32K -$74.8K -5 -71%
MLM
48
Mount Lucas Management
Pennsylvania
$30K +$15K +1 +100%
GC
49
Guggenheim Capital
Illinois
$28K – – –
Bank of America
50
Bank of America
North Carolina
$26K +$15K +1 +100%
1
2
3

TOVX Hedge Fund Activity: Q3 2016 in Review

60 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q3 2016, worth a combined $60.8M — down 5.3% from $64.2M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of TOVX and 6 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 17 added.

The largest buyer was BlackRock Fund Advisors, adding an estimated $150K. The largest seller was Bridgeway Capital Management, cutting an estimated $224K.

  • 60 institutional investors held Theriva Biologics (TOVX) as of Q3 2016, down from 61 in Q2 2016.
  • Funds reported $60.8M of Theriva Biologics stock for Q3 2016, down 5.3% quarter-over-quarter.
  • 6 funds opened new Theriva Biologics positions in Q3 2016 and 7 closed out, a net change of -1 holder.
  • The largest Theriva Biologics buyer in Q3 2016 was BlackRock Fund Advisors, an estimated $150K added.
  • The largest Theriva Biologics seller in Q3 2016 was Bridgeway Capital Management, an estimated $224K sold.

Based on aggregated 13F filings for Q3 2016.